Candel Therapeutics (CADL) said Wednesday it released final survival data from its phase 2a trial of CAN-2409 in advanced non-small cell lung cancer patients resistant to immune checkpoint inhibitor treatment.
The study demonstrated positive results, with a median overall survival of 24.5 months in the evaluable patients, surpassing standard care outcomes.
Key findings include a median overall survival of 21.5 months in patients with progressive disease despite ICI therapy, compared to 9.8 to 11.8 months with standard docetaxel chemotherapy. Additionally, 37% of patients survived beyond two years after receiving CAN-2409, while 69% showed regression in uninjected tumors, demonstrating an abscopal effect. Non-squamous NSCLC patients had the best outcomes, with a median overall survival of 25.4 months, the company said.
Throughout the long-term study, CAN-2409 maintained a strong safety profile and was well-tolerated by patients, Candel Therapeutics said.
Candel shares rose 2.5% in after-hours trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。